The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses

被引:301
作者
Prasad, Vinay [1 ]
Kim, Chul [1 ]
Burotto, Mauricio [1 ]
Vandross, Andrae [2 ]
机构
[1] NCI, Med Oncol Serv, NIH, Bethesda, MD 20892 USA
[2] Univ Calif Los Angeles, Div Med Oncol, Los Angeles, CA USA
关键词
PROGRESSION-FREE SURVIVAL; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; RANDOMIZED CONTROLLED-TRIALS; INDIVIDUAL PATIENT DATA; DISEASE-FREE SURVIVAL; ARRHYTHMIA SUPPRESSION TRIAL; ADVANCED COLORECTAL-CANCER; CLINICAL-TRIALS; POTENTIAL SURROGATE;
D O I
10.1001/jamainternmed.2015.2829
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The strength of association between surrogate end points and survival in oncology is important to understand because surrogate end points are frequently used in oncology clinical trials, supporting US Food and Drug Administration approvals and National Comprehensive Cancer Network guideline recommendations. OBJECTIVE To identify and evaluate trial-levelmeta-analyses of randomized clinical trials quantifying the association between a surrogate end point and overall survival in medical oncology. Trial-level correlations test whether treatments that improve the surrogate end point also improve the final end point and are widely considered the strongest evidence to validate a surrogate end point. EVIDENCE REVIEW Our literature search was built on earlier reported data sets and updated with Google Scholar and MEDLINE searches conducted on December 26, 2014. For MEDLINE, search terms included ("regression" or "correlation") and "surrogate" and "end point [or endpoint]" and ("oncology" or "cancer"). For Google scholar, search terms included ("regression" or "correlation") and "surrogate end point [or endpoint]" and "overall survival" and "trial level." A total of 108 abstracts were retrieved, and 62 articles were read in full in addition to articles identified through prior reviews. FINDINGS We found 36 articles in which 65 specific correlations between a surrogate end point and survival were identified. Surrogate end points were studied in the neoadjuvant, adjuvant, locally advanced, and metastatic settings. The most common sources for trials included in the 36 articles were systematic reviews of the published literature (10 of 36; 28%), and published literature and meeting abstracts (14 of 36; 39%). Four meta-analyses (11%) used a convenience sample, and only 5 studies (14%) attempted to include unpublished trials by surveying clinical trial registries. Among these 5 studies, only 352 of 684 eligible trials (51.1%) were included in the analyses. More than half of reported correlations (34 of 65; 52%) were of low strength (r <= 0.7). Approximately a quarter (16 of 65; 25%) were of medium strength (r > 0.7 tor < 0.85), and 15 of 65 (23%) were highly correlated (r >= 0.85) with survival. CONCLUSIONS AND RELEVANCE Most trial-level validation studies of surrogate end points in oncology find low correlations with survival. All validation studies use only a subset of available trials. The evidence supporting the use of surrogate end points in oncology is limited.
引用
收藏
页码:1389 / 1398
页数:10
相关论文
共 102 条
  • [1] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [2] Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
    Amir, Eitan
    Seruga, Bostjan
    Kwong, Ryan
    Tannock, Ian F.
    Ocana, Alberto
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 385 - 388
  • [3] Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
    Auperin, A.
    Le Chevalier, T.
    Le Pechoux, C.
    Pignon, J. P.
    Tribodet, H.
    Burdett, S.
    Stewart, L. A.
    Tierney, J. F.
    Stephens, R. J.
    Arriagada, R.
    Higgins, J. P.
    Johnson, D. H.
    van Meerbeeck, J.
    Parmar, M. K. B.
    Souhami, R. L.
    Bergman, B.
    Dautzenberg, B.
    Douillard, J. Y.
    Dunant, A.
    Endo, C.
    Girling, D. J.
    Imaizumi, M.
    Kato, H.
    Keller, S. M.
    Kimura, H.
    Knuuttila, A.
    Kodama, K.
    Komaki, R.
    Kris, M. G.
    Lad, T.
    Mineo, T.
    Park, J. H.
    Piantadosi, S.
    Pyrhonen, S.
    Rosell, R.
    Scagliotti, G. V.
    Seymour, L. W.
    Shepherd, F. A.
    Spiro, S. G.
    Strauss, G. M.
    Sylvester, R.
    Tada, H.
    Tanaka, F.
    Torri, V.
    Wada, H.
    Waller, D.
    Xu, G. C.
    [J]. LANCET, 2010, 375 (9722) : 1267 - 1277
  • [4] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
    Auperin, Anne
    Le Pechoux, Cecile
    Rolland, Estelle
    Curran, Walter J.
    Furuse, Kiyoyuki
    Fournel, Pierre
    Belderbos, Jose
    Clamon, Gerald
    Ulutin, Hakki Cuneyt
    Paulus, Rebecca
    Yamanaka, Takeharu
    Bozonnat, Marie-Cecile
    Uitterhoeve, Apollonia
    Wang, Xiaofei
    Stewart, Lesley
    Arriagada, Rodrigo
    Burdett, Sarah
    Pignon, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190
  • [5] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) : 520 - 529
  • [6] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [7] Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
    Berruti, Alfredo
    Amoroso, Vito
    Gallo, Fabio
    Bertaglia, Valentina
    Simoncini, Edda
    Pedersini, Rebecca
    Ferrari, Laura
    Bottini, Alberto
    Bruzzi, Paolo
    Sormani, Maria Pia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3883 - U288
  • [8] Progression-Free Survival: Meaningful or Simply Measurable?
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1030 - 1033
  • [9] Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
    Booth, Christopher M.
    Cescon, David W.
    Wang, Lisa
    Tannock, Ian F.
    Krzyzanowska, Monika K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5458 - 5464
  • [10] Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
    Bruzzi, P
    Del Mastro, L
    Sormani, MP
    Bastholt, L
    Danova, M
    Focan, C
    Fountzilas, G
    Paul, J
    Rosso, R
    Venturini, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5117 - 5125